Induction of severe systemic lupus erythematosus by TNF blockade and response to anti–IL-6 strategy
Because the disease did not respond to treatment with cyclophosphamide, we finally introduced infliximab to block the TNF pathway. [...]we strongly believe that clinical reasoning should involve consideration of the molecular effects of therapeutic interventions.
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2013-04, Vol.131 (4), p.1235-1237.e1 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1237.e1 |
|---|---|
| container_issue | 4 |
| container_start_page | 1235 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 131 |
| creator | Adler, Sabine, MD Kolev, Mirjam, MD Varisco, Pierre-Alain, MD Tham, Manuela von Gunten, Michael, MD Tappeiner, Christoph, MD Villiger, Peter M., MD |
| description | Because the disease did not respond to treatment with cyclophosphamide, we finally introduced infliximab to block the TNF pathway. [...]we strongly believe that clinical reasoning should involve consideration of the molecular effects of therapeutic interventions. |
| doi_str_mv | 10.1016/j.jaci.2012.09.034 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1555715016</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0091674912016132</els_id><sourcerecordid>3412287251</sourcerecordid><originalsourceid>FETCH-LOGICAL-c513t-d6c266748c78476e4362dff470e65b767604a007f1375f6e44c28d6a889e7b763</originalsourceid><addsrcrecordid>eNp9ks9u1DAQxi0EotvCC3BAlhDHBP-J7URCSFVFy0qr9tBytrzOBJxm48V2KuXGO_CGPEkd7UIlDpys0XzfN-OfBqE3lJSUUPmhL3tjXckIZSVpSsKrZ2hFSaMKWTPxHK0IaWghVdWcoNMYe5JrXjcv0QnjVFSk5isE67GdbHJ-xL7DER4gAI5zTLBzFg_TfooYwpy-w84kH3O1nfHd9SXeDt7emxawGVscIO79GAEnn-vkfv_8td4UEscUTIJv8yv0ojNDhNfH9wx9vfx8d_Gl2NxcrS_ON4UVlKeilZbJvG9tVV0pCRWXrO26ShGQYqukkqQyhKiOciW63K8sq1tp6roBlfv8DL075O6D_zFBTLr3UxjzSE2FEIqKzC2r2EFlg48xQKf3we1MmDUleiGre72Q1QtZTRqdyWbT22P0tN1B-9fyB2UWvD8KTLRm6IIZrYtPOsUEpWQJ-njQQQbx4CDoaB2MFloXwCbdevf_PT79Y7eDG12eeA8zxKf_6pg9-na5geUEaA6RlDP-CEMMq2M</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1555715016</pqid></control><display><type>article</type><title>Induction of severe systemic lupus erythematosus by TNF blockade and response to anti–IL-6 strategy</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Adler, Sabine, MD ; Kolev, Mirjam, MD ; Varisco, Pierre-Alain, MD ; Tham, Manuela ; von Gunten, Michael, MD ; Tappeiner, Christoph, MD ; Villiger, Peter M., MD</creator><creatorcontrib>Adler, Sabine, MD ; Kolev, Mirjam, MD ; Varisco, Pierre-Alain, MD ; Tham, Manuela ; von Gunten, Michael, MD ; Tappeiner, Christoph, MD ; Villiger, Peter M., MD</creatorcontrib><description>Because the disease did not respond to treatment with cyclophosphamide, we finally introduced infliximab to block the TNF pathway. [...]we strongly believe that clinical reasoning should involve consideration of the molecular effects of therapeutic interventions.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2012.09.034</identifier><identifier>PMID: 23154083</identifier><identifier>CODEN: JACIBY</identifier><language>eng</language><publisher>New York, NY: Mosby, Inc</publisher><subject>Aged ; Allergy and Immunology ; Anti-Inflammatory Agents, Non-Steroidal - therapeutic use ; Antibodies, Antinuclear - blood ; Antibodies, Antinuclear - immunology ; Antibodies, Monoclonal - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Autoimmune diseases ; Biological and medical sciences ; Bone marrow ; Drug therapy ; Endocarditis - drug therapy ; Endocarditis - etiology ; Endocarditis - immunology ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunopathology ; Inflammation - immunology ; Inflammation - pathology ; Infliximab ; Interleukin-6 - antagonists & inhibitors ; Interleukin-6 - immunology ; Lupus ; Lupus Erythematosus, Systemic - drug therapy ; Lupus Erythematosus, Systemic - etiology ; Lupus Erythematosus, Systemic - immunology ; Male ; Medical sciences ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Scleritis - drug therapy ; Scleritis - immunology ; Scleritis - pathology ; Tumor Necrosis Factor-alpha - antagonists & inhibitors ; Tumor Necrosis Factor-alpha - immunology</subject><ispartof>Journal of allergy and clinical immunology, 2013-04, Vol.131 (4), p.1235-1237.e1</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2012 American Academy of Allergy, Asthma & Immunology</rights><rights>2014 INIST-CNRS</rights><rights>Copyright Elsevier Limited Apr 2013</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c513t-d6c266748c78476e4362dff470e65b767604a007f1375f6e44c28d6a889e7b763</citedby><cites>FETCH-LOGICAL-c513t-d6c266748c78476e4362dff470e65b767604a007f1375f6e44c28d6a889e7b763</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.jaci.2012.09.034$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27251104$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23154083$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Adler, Sabine, MD</creatorcontrib><creatorcontrib>Kolev, Mirjam, MD</creatorcontrib><creatorcontrib>Varisco, Pierre-Alain, MD</creatorcontrib><creatorcontrib>Tham, Manuela</creatorcontrib><creatorcontrib>von Gunten, Michael, MD</creatorcontrib><creatorcontrib>Tappeiner, Christoph, MD</creatorcontrib><creatorcontrib>Villiger, Peter M., MD</creatorcontrib><title>Induction of severe systemic lupus erythematosus by TNF blockade and response to anti–IL-6 strategy</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>Because the disease did not respond to treatment with cyclophosphamide, we finally introduced infliximab to block the TNF pathway. [...]we strongly believe that clinical reasoning should involve consideration of the molecular effects of therapeutic interventions.</description><subject>Aged</subject><subject>Allergy and Immunology</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</subject><subject>Antibodies, Antinuclear - blood</subject><subject>Antibodies, Antinuclear - immunology</subject><subject>Antibodies, Monoclonal - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Autoimmune diseases</subject><subject>Biological and medical sciences</subject><subject>Bone marrow</subject><subject>Drug therapy</subject><subject>Endocarditis - drug therapy</subject><subject>Endocarditis - etiology</subject><subject>Endocarditis - immunology</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunopathology</subject><subject>Inflammation - immunology</subject><subject>Inflammation - pathology</subject><subject>Infliximab</subject><subject>Interleukin-6 - antagonists & inhibitors</subject><subject>Interleukin-6 - immunology</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Lupus Erythematosus, Systemic - etiology</subject><subject>Lupus Erythematosus, Systemic - immunology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</subject><subject>Scleritis - drug therapy</subject><subject>Scleritis - immunology</subject><subject>Scleritis - pathology</subject><subject>Tumor Necrosis Factor-alpha - antagonists & inhibitors</subject><subject>Tumor Necrosis Factor-alpha - immunology</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9ks9u1DAQxi0EotvCC3BAlhDHBP-J7URCSFVFy0qr9tBytrzOBJxm48V2KuXGO_CGPEkd7UIlDpys0XzfN-OfBqE3lJSUUPmhL3tjXckIZSVpSsKrZ2hFSaMKWTPxHK0IaWghVdWcoNMYe5JrXjcv0QnjVFSk5isE67GdbHJ-xL7DER4gAI5zTLBzFg_TfooYwpy-w84kH3O1nfHd9SXeDt7emxawGVscIO79GAEnn-vkfv_8td4UEscUTIJv8yv0ojNDhNfH9wx9vfx8d_Gl2NxcrS_ON4UVlKeilZbJvG9tVV0pCRWXrO26ShGQYqukkqQyhKiOciW63K8sq1tp6roBlfv8DL075O6D_zFBTLr3UxjzSE2FEIqKzC2r2EFlg48xQKf3we1MmDUleiGre72Q1QtZTRqdyWbT22P0tN1B-9fyB2UWvD8KTLRm6IIZrYtPOsUEpWQJ-njQQQbx4CDoaB2MFloXwCbdevf_PT79Y7eDG12eeA8zxKf_6pg9-na5geUEaA6RlDP-CEMMq2M</recordid><startdate>20130401</startdate><enddate>20130401</enddate><creator>Adler, Sabine, MD</creator><creator>Kolev, Mirjam, MD</creator><creator>Varisco, Pierre-Alain, MD</creator><creator>Tham, Manuela</creator><creator>von Gunten, Michael, MD</creator><creator>Tappeiner, Christoph, MD</creator><creator>Villiger, Peter M., MD</creator><general>Mosby, Inc</general><general>Elsevier</general><general>Elsevier Limited</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20130401</creationdate><title>Induction of severe systemic lupus erythematosus by TNF blockade and response to anti–IL-6 strategy</title><author>Adler, Sabine, MD ; Kolev, Mirjam, MD ; Varisco, Pierre-Alain, MD ; Tham, Manuela ; von Gunten, Michael, MD ; Tappeiner, Christoph, MD ; Villiger, Peter M., MD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c513t-d6c266748c78476e4362dff470e65b767604a007f1375f6e44c28d6a889e7b763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Aged</topic><topic>Allergy and Immunology</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - therapeutic use</topic><topic>Antibodies, Antinuclear - blood</topic><topic>Antibodies, Antinuclear - immunology</topic><topic>Antibodies, Monoclonal - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Autoimmune diseases</topic><topic>Biological and medical sciences</topic><topic>Bone marrow</topic><topic>Drug therapy</topic><topic>Endocarditis - drug therapy</topic><topic>Endocarditis - etiology</topic><topic>Endocarditis - immunology</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunopathology</topic><topic>Inflammation - immunology</topic><topic>Inflammation - pathology</topic><topic>Infliximab</topic><topic>Interleukin-6 - antagonists & inhibitors</topic><topic>Interleukin-6 - immunology</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Lupus Erythematosus, Systemic - etiology</topic><topic>Lupus Erythematosus, Systemic - immunology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis</topic><topic>Scleritis - drug therapy</topic><topic>Scleritis - immunology</topic><topic>Scleritis - pathology</topic><topic>Tumor Necrosis Factor-alpha - antagonists & inhibitors</topic><topic>Tumor Necrosis Factor-alpha - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Adler, Sabine, MD</creatorcontrib><creatorcontrib>Kolev, Mirjam, MD</creatorcontrib><creatorcontrib>Varisco, Pierre-Alain, MD</creatorcontrib><creatorcontrib>Tham, Manuela</creatorcontrib><creatorcontrib>von Gunten, Michael, MD</creatorcontrib><creatorcontrib>Tappeiner, Christoph, MD</creatorcontrib><creatorcontrib>Villiger, Peter M., MD</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Adler, Sabine, MD</au><au>Kolev, Mirjam, MD</au><au>Varisco, Pierre-Alain, MD</au><au>Tham, Manuela</au><au>von Gunten, Michael, MD</au><au>Tappeiner, Christoph, MD</au><au>Villiger, Peter M., MD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Induction of severe systemic lupus erythematosus by TNF blockade and response to anti–IL-6 strategy</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2013-04-01</date><risdate>2013</risdate><volume>131</volume><issue>4</issue><spage>1235</spage><epage>1237.e1</epage><pages>1235-1237.e1</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><coden>JACIBY</coden><abstract>Because the disease did not respond to treatment with cyclophosphamide, we finally introduced infliximab to block the TNF pathway. [...]we strongly believe that clinical reasoning should involve consideration of the molecular effects of therapeutic interventions.</abstract><cop>New York, NY</cop><pub>Mosby, Inc</pub><pmid>23154083</pmid><doi>10.1016/j.jaci.2012.09.034</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2013-04, Vol.131 (4), p.1235-1237.e1 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_journals_1555715016 |
| source | MEDLINE; Access via ScienceDirect (Elsevier); EZB-FREE-00999 freely available EZB journals |
| subjects | Aged Allergy and Immunology Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antibodies, Antinuclear - blood Antibodies, Antinuclear - immunology Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Autoimmune diseases Biological and medical sciences Bone marrow Drug therapy Endocarditis - drug therapy Endocarditis - etiology Endocarditis - immunology Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunopathology Inflammation - immunology Inflammation - pathology Infliximab Interleukin-6 - antagonists & inhibitors Interleukin-6 - immunology Lupus Lupus Erythematosus, Systemic - drug therapy Lupus Erythematosus, Systemic - etiology Lupus Erythematosus, Systemic - immunology Male Medical sciences Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis Scleritis - drug therapy Scleritis - immunology Scleritis - pathology Tumor Necrosis Factor-alpha - antagonists & inhibitors Tumor Necrosis Factor-alpha - immunology |
| title | Induction of severe systemic lupus erythematosus by TNF blockade and response to anti–IL-6 strategy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-20T20%3A50%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Induction%20of%20severe%20systemic%20lupus%20erythematosus%20by%20TNF%20blockade%20and%20response%20to%20anti%E2%80%93IL-6%20strategy&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Adler,%20Sabine,%20MD&rft.date=2013-04-01&rft.volume=131&rft.issue=4&rft.spage=1235&rft.epage=1237.e1&rft.pages=1235-1237.e1&rft.issn=0091-6749&rft.eissn=1097-6825&rft.coden=JACIBY&rft_id=info:doi/10.1016/j.jaci.2012.09.034&rft_dat=%3Cproquest_cross%3E3412287251%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1555715016&rft_id=info:pmid/23154083&rft_els_id=1_s2_0_S0091674912016132&rfr_iscdi=true |